Primary Biliary Cholangitis (CNP-104)

CNP-104 is a first-in-class therapeutic designed to reprogram the immune system to address the immunological root cause of disease in PBC, prevent immune-mediated destruction of the liver bile ducts, and provide long-term therapeutic benefit by allowing recovery of the damaged liver tissues.

COUR aims to file an IND for CNP-104 in 2021.